Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Balis Website

Frank M. Balis, M.D.

Selected Publications
1)  Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Clin. Cancer Res. 14: 1111-5, 2008. [Journal]
2)  Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
Oncologist. 13: 679-89, 2008. [Journal]
3)  Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Blood. 111: 566-73, 2008. [Journal]
4)  Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, Aikin A, Whitcomb P, Renbarger J, Lieberman FS, Berg SL, Blaney SM.
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
Cancer Chemother. Pharmacol. 62: 355-361, 2008. [Journal]
5)  Warren KE, McCully C, Dvinge H, Tjornelund J, Sehested M, Lichenstein HS, Balis FM.
Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Cancer Chemother. Pharmacol. 62: 433-7, 2008. [Journal]
6)  Meany HJ, Fox E, McCully C, Tucker C, Balis FM.
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Cancer Chemother. Pharmacol. 62: 387-392, 2008. [Journal]
7)  Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, Korf BR, Babovic-Vuksanovic D, Packer RJ, Belasco J, Goldman S, Jakacki R, Kieran M, Steinberg SM, Widemann BC.
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Neurology. 68: 643-7, 2007. [Journal]
8)  Cho SY, Fox E, McCully C, Bauch J, Marsh K, Balis FM.
Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates.
Cancer Chemother. Pharmacol. 60: 563-7, 2007. [Journal]
9)  Turingan RS, Liu C, Hawkins ME, Martin CT.
Structural confirmation of a bent and open model for the initiation complex of T7 RNA polymerase.
Biochemistry. 46: 1714-23, 2007. [Journal]
10)  Hawkins ME.
Synthesis, purification and sample experiment for fluorescent pteridine-containing DNA: tools for studying DNA interactive systems.
Nature protocols. 2: 1013-21, 2007. [Journal]
11)  Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Clin. Cancer Res. 12: 4882-7, 2006. [Journal]
12)  Adamson PC, Matthay KK, O'brien M, Reaman GH, Sato JK, Balis FM.
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
Pediatr Blood Cancer. 2006. [Journal]
13)  Augustyn KE, Wojtuszewski K, Hawkins ME, Knutson JR, Mukerji I.
Examination of the premelting transition of DNA A-tracts using a fluorescent adenosine analogue.
Biochemistry. 45: 5039-47, 2006. [Journal]
14)  Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM.
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
J. Clin. Oncol. 24: 507-16, 2006. [Journal]
15)  Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM.
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
Cancer Chemother. Pharmacol. 58: 343-7, 2006. [Journal]
16)  Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia JP, Steinberg SM, Balis FM, Adamson PC.
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative children's oncology group/national cancer institute pilot trial (CCG-1942).
Pediatr Blood Cancer. 2006. [Journal]
17)  Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, Bleyer WA.
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.
Leuk. Lymphoma. 47: 2488-504, 2006. [Journal]
18)  Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T.
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Cancer. 103: 1932-8, 2005. [Journal]
19)  Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, Clark G, Gantz SB, Venzon D, Zujewski J.
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Clin Cancer Res. 11: 1247-52, 2005. [Journal]
20)  Blaney SM, Balis FM, Berg S, Arndt CA, Heideman R, Geyer JR, Packer R, Adamson PC, Jaeckle K, Klenke R, Aikin A, Murphy R, McCully C, Poplack DG.
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
J Clin Oncol. 23: 1555-63, 2005. [Journal]
21)  Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM.
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
J. Clin. Oncol. 23: 7646-53, 2005. [Journal]
22)  Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM.
Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Clin Cancer Res. 11: 1669-74, 2005. [Journal]
23)  Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL.
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Pediatrics. 116: e846-54, 2005. [Journal]
24)  Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T.
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Mutat Res. 583: 105-19, 2005. [Journal]
25)  Stanley RJ, Hou Z, Yang A, Hawkins ME.
The two photon excitation cross section of 6MAP, a fluorescent adenine analog.
J Physical Chem. 109: 3690-5, 2005. [Journal]
26)  Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clin Cancer Res. 10: 4724-33, 2004. [Journal]
27)  Shchyolkina AK, Kaluzhny DN, Borisova OF, Hawkins ME, Jernigan RL, Jovin TM, Arndt-Jovin DJ, Zhurkin VB.
Formation of an intramolecular triple-stranded DNA structure monitored by fluorescence of 2-aminopurine or 6-methylisoxanthopterin.
Nucleic Acids Res. 32: 432-40, 2004. [Journal]
28)  Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC.
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Cancer. 100: 2222-32, 2004. [Journal]
29)  Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ.
Loss of Smad3 in acute T-cell lymphoblastic leukemia.
N Engl J Med. 351: 552-9, 2004. [Journal]
30)  Sanabia JE, Goldner LS, Lacaze PA, Hawkins ME.
On the feasibility of single-molecule detection of the guanosine analogue 3-MI.
J Physical Chem. 108: 15293-300, 2004. [Journal]
31)  Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM.
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
Cancer Chemother Pharmacol. 53: 482-8, 2004. [Journal]
32)  Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Cancer Chemother Pharmacol. 54: 206-12, 2004. [Journal]
33)  Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Cancer Chemother Pharmacol. 54: 206-12, 2004. [Journal]
34)  Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM.
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
Clin Cancer Res. 10: 2525-9, 2004. [Journal]
35)  Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty JF, Yale K, Poblenz M, Kearney BP, Zhong L, Coakley DF, Blanche S, Bresson JL, Zuckerman JA, Zeichner SL.
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Antimicrob Agents Chemother. 48: 124-9, 2004. [Journal]
36)  Widemann BC, Balis FM, Shalabi A, Boron M, O'Brien M, Cole DE, Jayaprakash N, Ivy P, Castle V, Muraszko K, Moertel CL, Trueworthy R, Hermann RC, Moussa A, Hinton S, Reaman G, Poplack D, Adamson PC.
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
J Natl Cancer Inst. 96: 1557-9, 2004. [Journal]
37)  Hawkins ME, Balis FM.
Use of pteridine nucleoside analogs as hybridization probes.
Nucleic Acids Res. 32: e62, 2004. [Journal]
38)  Salzer W, Steinberg SM, Liewehr DJ, Freifeld A, Balis FM, Widemann BC.
Evaluation and treatment of fever in the non-neutropenic child with cancer.
J Pediatr Hematol Oncol. 25: 606-12, 2003. [Journal]
39)  Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC.
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Clin Cancer Res. 9: 650-6, 2003. [Journal]
40)  Thompson P, Balis F, Serabe BM, Berg S, Adamson P, Klenke R, Aiken A, Packer R, Murry DJ, Jakacki R, Blaney SM.
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Cancer Chemother Pharmacol. 52: 417-23, 2003. [Journal]
41)  Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM.
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.
J Clin Oncol. 21: 143-7, 2003. [Journal]
42)  Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
J Clin Oncol. 21: 1866-73, 2003. [Journal]
43)  Patel M, McCully C, Godwin K, Balis FM.
Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
J Neurooncol. 61: 203-7, 2003. [Journal]
44)  Fox E, Curt GA, Balis FM.
Clinical trial design for target-based therapy.
Oncologist. 7: 401-9, 2002. [Journal]
45)  Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Blood. 99: 2685-93, 2002. [Journal]
46)  Balis FM.
Evolution of anticancer drug discovery and the role of cell-based screening.
J Natl Cancer Inst. 94: 78-9, 2002. [Journal]
47)  Balis FM.
Evolution of anticancer drug discovery and the role of cell-based screening.
J Natl Cancer Inst. 94: 78-9, 2002. [Journal]
48)  Lutz RJ, Warren K, Balis F, Patronas N, Dedrick RL.
Mixing during intravertebral arterial infusions in an in vitro model.
J Neurooncol. 58: 95-106, 2002. [Journal]
49)  Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM.
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.
Clin Cancer Res. 8: 2437-42, 2002. [Journal]
50)  Fox E, Bungay PM, Bacher J, McCully CL, Dedrick RL, Balis FM.
Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey.
J Pharmacol Exp Ther. 301: 1003-11, 2002. [Journal]
51)  Adamson PC, Widemann BC, Reaman GH, Seibel NL, Murphy RF, Gillespie AF, Balis FM.
A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
Clin Cancer Res. 7: 3034-9, 2001. [Journal]
52)  Warren KE, Patronas N, Aikin AA, Albert PS, Balis FM.
Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.
J Natl Cancer Inst. 93: 1401-5, 2001. [Journal]
53)  Salzer W, Widemann B, McCully C, Adamson PC, Balis FM.
Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
Cancer Chemother Pharmacol. 48: 235-40, 2001. [Journal]
54)  Grem JL, Quinn M, Ismail AS, Takimoto CH, Lush R, Liewehr DJ, Steinberg SM, Balis FM, Chen AP, Monahan BP, Harold N, Corse W, Pang J, Murphy RF, Allegra CJ, Hamilton JM.
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Cancer Chemother Pharmacol. 47: 117-25, 2001. [Journal]
55)  Warren KE, Patel MC, Aikin AA, Widemann B, Libucha M, Adamson PC, Neuwirth R, Benziger D, O'Toole T, Ford K, Patronas N, Packer RJ, Balis FM.
Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.
Cancer Chemother Pharmacol. 48: 275-82, 2001. [Journal]
56)  Lowe ES, Kitchen BJ, Erdmann G, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Woods W, Franklin J, Widemann BC, Balis FM, Murphy RF, Adamson PC.
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
Cancer Chemother Pharmacol. 47: 199-205, 2001. [Journal]
57)  Bungay PM, Dedrick RL, Fox E, Balis FM.
Probe calibration in transient microdialysis in vivo.
Pharm Res. 18: 361-6, 2001. [Journal]
58)  Hawkins ME, Pfleiderer W, Jungmann O, Balis FM.
Synthesis and fluorescence characterization of pteridine adenosine nucleoside analogs for DNA incorporation.
Anal Biochem. 298: 231-40, 2001. [Journal]
59)  Balis FM.
Clinical trials in childhood cancers.
Oncologist. 5: xii-xiii, 2000. [Journal]
60)  Warren KE, McCully CM, Walsh TJ, Balis FM.
Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.
Antimicrob Agents Chemother. 44: 1100-1, 2000. [Journal]
61)  Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM.
Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates.
Cancer Chemother Pharmacol. 45: 207-12, 2000. [Journal]
62)  Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG.
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration.
Cancer Chemother Pharmacol. 45: 259-64, 2000. [Journal]
63)  Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A.
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clin Cancer Res. 6: 415-21, 2000. [Journal]
64)  Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS, McCully C, Hawkins M, Adamson PC.
Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
J Pharmacol Exp Ther. 294: 894-901, 2000. [Journal]
65)  Long L, Berg SL, Roy SK, McCully CL, Song-Yoo HW, Moschel RC, Balis FM, Dolan ME.
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates.
Clin Cancer Res. 6: 3662-9, 2000. [Journal]
66)  Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM.
Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.
J Clin Oncol. 18: 1020-6, 2000. [Journal]
67)  Moser AM, Patel M, Yoo H, Balis FM, Hawkins ME.
Real-time fluorescence assay for O6-alkylguanine-DNA alkyltransferase.
Anal Biochem. 281: 216-22, 2000. [Journal]

This page was last updated on 8/6/2008.